全球抗體藥物複合體（ADC）市場規模、佔有率、趨勢和成長分析報告：2026-2034年

抗體藥物複合體(ADC) 市場預計將從 2025 年的 187.5 億美元成長到 2034 年的 427.5 億美元，2026 年至 2034 年的複合年成長率為 9.59%。

由於標靶癌症治療的突破性進展，全球抗體藥物複合體（ADC）市場正經歷快速成長。 ADC將單株抗體與強效細胞毒性藥物結合，能夠將藥物精準遞送至癌細胞，同時最大限度地減少對健康組織的損傷。近年來，全球癌症發生率的上升和對個人化醫療需求的日益成長，顯著推動了市場擴張。

成長要素包括對腫瘤學研究的大力投入、不斷擴大的臨床試驗項目管線以及創新型抗體偶聯藥物（ADC）療法的監管核准。製藥公司正與生物技術公司合作，以改善連接子技術和有效載荷效率。生物標記辨識和伴隨診斷技術的進步也增強了ADC的臨床成功率，並加速了其在多種癌症適應症的應用。

抗體藥物偶聯物（ADC）市場前景仍十分光明，眾多候選藥物正處於後期研發階段。抗體工程和藥物偶聯技術的創新可望進一步提升其療效和安全性。隨著醫療體係日益重視標靶治療和精準腫瘤學，ADC有望在癌症治療中發揮變革性作用，並推動市場持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球抗體藥物複合體（ADC）市場：依應用領域分類

• 市場分析、洞察與預測
• 血癌
• 白血病
• 淋巴瘤
• 多發性骨髓瘤
• 乳癌
• 尿路上皮癌/膀胱癌
• 其他

第5章 全球抗體藥物複合體（ADC）市場：依產品分類

• 市場分析、洞察與預測
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• 其他

第6章 全球抗體藥物複合體(ADC) 市場：以標靶分類

• 市場分析、洞察與預測
• HER2
• CD22
• CD30
• 其他

第7章 全球抗體藥物複合體（ADC）市場：依技術分類

• 市場分析、洞察與預測
• 類型
• 可切割連接器
• 不可分割的連接子
• 無連接器

第8章 全球抗體藥物複合體(ADC) 市場：依連接子技術類型分類

• 市場分析、洞察與預測
• VC
• Sulfo-SPDB
• VA
• Hydrazone
• 其他

第9章 全球抗體藥物複合體（ADC）市場：依有效載荷技術分類

• 市場分析、洞察與預測
• MMAE
• MMAF
• DM4
• 喜樹鹼
• 其他

第10章 全球抗體藥物複合體（ADC）市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Seagen Inc
  • Takeda Pharmaceutical Company Ltd
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Gilead Sciences Inc
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Astellas Pharma Inc
  • ADC Therapeutics SA

The Antibody Drug Conjugates Market size is expected to reach USD 42.75 Billion in 2034 from USD 18.75 Billion (2025) growing at a CAGR of 9.59% during 2026-2034.

The Global Antibody Drug Conjugates (ADC) Market has experienced rapid growth due to breakthroughs in targeted cancer therapies. ADCs combine monoclonal antibodies with potent cytotoxic drugs, enabling precise delivery to cancer cells while minimizing damage to healthy tissue. Rising cancer prevalence worldwide and increasing demand for personalized medicine have significantly propelled market expansion over recent years.

Growth drivers include strong investment in oncology research, expanding clinical trial pipelines, and regulatory approvals for innovative ADC therapies. Pharmaceutical companies are collaborating with biotechnology firms to enhance linker technologies and payload efficiency. Advances in biomarker identification and companion diagnostics have also strengthened the clinical success of ADCs, driving their adoption in various cancer indications.

Future prospects for the ADC market remain highly promising, with numerous candidates in late-stage development. Technological innovations in antibody engineering and drug conjugation methods are expected to improve efficacy and safety profiles. As healthcare systems prioritize targeted therapies and precision oncology, ADCs are likely to play a transformative role in cancer treatment, supporting sustained market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Blood Cancer
• Leukemia
• Lymphoma
• Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Target

• HER2
• CD22
• CD30
• Others

By Technology

• Type
• Cleavable Linker
• Non-cleavable Linker
• Linker less

By Linker Technology Type

• VC
• Sulfo-SPDB
• VA
• Hydrazone
• Others

By Payload Technology

• MMAE
• MMAF
• DM4
• Camptothecin
• Others

COMPANIES PROFILED

• Seagen Inc, Takeda Pharmaceutical Company Ltd, AstraZeneca, F HoffmannLa Roche Ltd, Pfizer Inc, Gilead Sciences Inc, Daiichi Sankyo Company Ltd, GlaxoSmithKline Plc, Astellas Pharma Inc, ADC Therapeutics SA

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Urothelial Cancer & Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Kadcyla Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Enhertu Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Adcetris Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Padcev Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Trodelvy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Polivy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY TARGET 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Target
• 6.2. HER2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. CD22 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CD30 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Type Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Non-cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Linker less Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY LINKER TECHNOLOGY TYPE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Linker Technology Type
• 8.2. VC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Sulfo-SPDB Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. VA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Hydrazone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY PAYLOAD TECHNOLOGY 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Payload Technology
• 9.2. MMAE Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. MMAF Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. DM4 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Camptothecin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Application
  • 10.2.2 By Product
  • 10.2.3 By Target
  • 10.2.4 By Technology
  • 10.2.5 By Linker Technology Type
  • 10.2.6 By Payload Technology
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Application
  • 10.3.2 By Product
  • 10.3.3 By Target
  • 10.3.4 By Technology
  • 10.3.5 By Linker Technology Type
  • 10.3.6 By Payload Technology
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Application
  • 10.4.2 By Product
  • 10.4.3 By Target
  • 10.4.4 By Technology
  • 10.4.5 By Linker Technology Type
  • 10.4.6 By Payload Technology
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Application
  • 10.5.2 By Product
  • 10.5.3 By Target
  • 10.5.4 By Technology
  • 10.5.5 By Linker Technology Type
  • 10.5.6 By Payload Technology
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Application
  • 10.6.2 By Product
  • 10.6.3 By Target
  • 10.6.4 By Technology
  • 10.6.5 By Linker Technology Type
  • 10.6.6 By Payload Technology
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL ANTIBODY DRUG CONJUGATES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Seagen Inc
  • 12.2.2 Takeda Pharmaceutical Company Ltd
  • 12.2.3 AstraZeneca
  • 12.2.4 F. Hoffmann-La Roche Ltd
  • 12.2.5 Pfizer Inc
  • 12.2.6 Gilead Sciences Inc
  • 12.2.7 Daiichi Sankyo Company Ltd
  • 12.2.8 GlaxoSmithKline Plc
  • 12.2.9 Astellas Pharma Inc
  • 12.2.10 ADC Therapeutics SA